This was achieved first by profiling the heterogeneity of survival dependence of a panel of SCLC cell lines on the BCL-2 family anti-apoptotic proteins by BH3 mimetic screening, where we used BH3 mimetics to target specific BCL-2 anti-apoptotic proteins followed by measurement of cell viability [21]. This evidence concerns the gene BCL2 and small cell lung carcinoma.